Jiangsu Aidea Pharmaceutical Group Co., Ltd. (SHA:688488)
China · Delayed Price · Currency is CNY 16.94
+0.46 (2.79%)
At close: Mar 6, 2026
SHA:688488 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 720.67 | 415.54 | 409.06 | 242.86 | 254.97 |
Other Revenue | - | 2.26 | 2.3 | 1.36 | 0.74 |
| 720.67 | 417.8 | 411.36 | 244.22 | 255.71 | |
Revenue Growth (YoY) | 72.49% | 1.57% | 68.44% | -4.49% | -11.54% |
Cost of Revenue | - | 224.53 | 245.01 | 172.18 | 181.33 |
Gross Profit | 720.67 | 193.28 | 166.36 | 72.04 | 74.38 |
Selling, General & Admin | - | 251.95 | 199.69 | 167.57 | 88.24 |
Research & Development | - | 89.89 | 63.18 | 63.91 | 47.67 |
Other Operating Expenses | 672.92 | 5.61 | 5.95 | 3.33 | 3.31 |
Operating Expenses | 672.92 | 344.85 | 272.56 | 243.68 | 136.73 |
Operating Income | 47.75 | -151.58 | -106.2 | -171.64 | -62.34 |
Interest Expense | - | -15.36 | -11.76 | -3.92 | -0.25 |
Interest & Investment Income | - | 9.49 | 14.1 | 9.67 | 10.47 |
Currency Exchange Gain (Loss) | - | 0.02 | -0.1 | 0.88 | -0.2 |
Other Non Operating Income (Expenses) | -23.44 | -0.13 | -0.08 | -0.11 | -0.09 |
EBT Excluding Unusual Items | 24.3 | -157.56 | -104.04 | -165.11 | -52.41 |
Impairment of Goodwill | - | -0.63 | - | - | - |
Gain (Loss) on Sale of Investments | - | 10.76 | 1.54 | 7.19 | 0.31 |
Gain (Loss) on Sale of Assets | - | -0.47 | -0.06 | -0.28 | 1.58 |
Asset Writedown | - | -28.33 | - | - | - |
Other Unusual Items | - | 10.23 | 10.47 | 15.82 | 8.25 |
Pretax Income | 24.3 | -166 | -92.09 | -142.38 | -42.27 |
Income Tax Expense | 44.04 | -27.16 | -16.02 | -18.29 | -12.29 |
Earnings From Continuing Operations | -19.73 | -138.84 | -76.07 | -124.09 | -29.99 |
Minority Interest in Earnings | - | -2.37 | - | - | - |
Net Income | -19.73 | -141.2 | -76.07 | -124.09 | -29.99 |
Net Income to Common | -19.73 | -141.2 | -76.07 | -124.09 | -29.99 |
Shares Outstanding (Basic) | 395 | 421 | 423 | 414 | 428 |
Shares Outstanding (Diluted) | 395 | 421 | 423 | 414 | 428 |
Shares Change (YoY) | -6.20% | -0.44% | 2.17% | -3.44% | 7.71% |
EPS (Basic) | -0.05 | -0.34 | -0.18 | -0.30 | -0.07 |
EPS (Diluted) | -0.05 | -0.34 | -0.18 | -0.30 | -0.07 |
Free Cash Flow | - | -82.06 | -237.43 | -232.85 | -107.15 |
Free Cash Flow Per Share | - | -0.20 | -0.56 | -0.56 | -0.25 |
Gross Margin | 100.00% | 46.26% | 40.44% | 29.50% | 29.09% |
Operating Margin | 6.63% | -36.28% | -25.82% | -70.28% | -24.38% |
Profit Margin | -2.74% | -33.80% | -18.49% | -50.81% | -11.73% |
Free Cash Flow Margin | - | -19.64% | -57.72% | -95.34% | -41.90% |
EBITDA | 95.2 | -104.12 | -64.27 | -138.39 | -35.09 |
EBITDA Margin | 13.21% | -24.92% | -15.62% | -56.66% | -13.72% |
D&A For EBITDA | 47.45 | 47.45 | 41.93 | 33.26 | 27.25 |
EBIT | 47.75 | -151.58 | -106.2 | -171.64 | -62.34 |
EBIT Margin | 6.63% | -36.28% | -25.82% | -70.28% | -24.38% |
Effective Tax Rate | 181.19% | - | - | - | - |
Revenue as Reported | - | 417.8 | 411.36 | 244.22 | 255.71 |
Advertising Expenses | - | - | - | 2.69 | 1.56 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.